TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta (NeoRecormon ®) | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: epoetin beta (NeoRecormon ®); Assigned to Arm(s): A
C: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: QM; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Q2W, QM
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): 2
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
D: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2
B: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
D: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke
Brief Summary: Primary objective:

* To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.

Secondary objectives:

* To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization
* To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization
* To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke


Options:
A: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
B: Arm Label: Dabigatran therapy; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Acetylsalicylic Acid thereapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran therapy | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylsalicylic Acid thereapy
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
D: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke
Brief Summary: Primary objective:

* To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.

Secondary objectives:

* To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization
* To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization
* To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke


Options:
A: Arm Label: Heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Drug: Placebo | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Heparin, Drug: Nadroparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin, Placebo | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Heparin, Nadroparin
B: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia
Brief Summary: The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.


Options:
A: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
C: Arm Label: Olanzapine or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amisulpride, Drug: Olanzapine and Amisulpride | Arm Label: Amisulpride or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Olanzapine and Amisulpride | Arm Label: Olanzapine and Amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Amisulpride | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine and Amisulpride | Intervention Type: DRUG; Name: Amisulpride; Assigned to Arm(s): Olanzapine and Amisulpride, Olanzapine or Placebo | Intervention Type: DRUG; Name: Olanzapine and Amisulpride; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine or Placebo
D: Arm Label: Risperidone, Intensive; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: risperidone, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: olanzapine, intensive; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: olanzapine, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: aripiprazole, intensive; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: aripiprazole, basiv; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone, Intensive, risperidone, basic | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, basic, olanzapine, intensive | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): aripiprazole, basiv, aripiprazole, intensive

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules
Brief Summary: The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.


Options:
A: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A
B: Arm Label: Interim Buprenorphine Treatment; Type: EXPERIMENTAL; Interventions: Drug: Interim Buprenorphine Treatment (IBT) | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interim Buprenorphine Treatment (IBT); Assigned to Arm(s): Interim Buprenorphine Treatment
C: Arm Label: Buprenorphine/Nx; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): Buprenorphine/Nx | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone
D: Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: Buprenorphine/naloxone; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): Buprenorphine/naloxone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules
Brief Summary: The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.


Options:
A: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Linkage; Type: EXPERIMENTAL; Interventions: Behavioral: Linkage | Intervention Type: BEHAVIORAL; Name: Linkage; Assigned to Arm(s): Linkage
B: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine
C: Arm Label: Active electroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroacupuncture | Arm Label: Sham electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Electroacupuncture | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Active electroacupuncture, Sham electroacupuncture
D: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules
Brief Summary: The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.


Options:
A: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): 3
B: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Linkage; Type: EXPERIMENTAL; Interventions: Behavioral: Linkage | Intervention Type: BEHAVIORAL; Name: Linkage; Assigned to Arm(s): Linkage
C: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A

Answer: D